<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820027</url>
  </required_header>
  <id_info>
    <org_study_id>0663-098</org_study_id>
    <secondary_id>2009_502</secondary_id>
    <nct_id>NCT00820027</nct_id>
  </id_info>
  <brief_title>Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK0663/Etoricoxib and Ibuprofen in the Treatment of Postorthopedic Knee Replacement Surgery Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to
      placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total
      knee replacement surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Intensity Difference at Rest (etoricoxib 120 mg/ 90 mg to placebo)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Total Daily Dose of Morphine (etoricoxib 120 mg/90 mg to placebo)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Pain Intensity Difference at Rest (etoricoxib 120 mg/ 90 mg to ibuprofen 1800 mg)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average total Daily Dose of Morphine (etoricoxib 120 mg/90 mg to ibuprofen 1800 mg)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">776</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 1800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 90 mg</intervention_name>
    <description>One 90 mg tablet once daily</description>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 120 mg</intervention_name>
    <description>Two 60 mg tablets once daily</description>
    <arm_group_label>Etoricoxib 120 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg</intervention_name>
    <description>One tablet three times daily</description>
    <arm_group_label>Ibuprofen 1800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for Etoricoxib 120 mg</intervention_name>
    <description>Two tablets once daily</description>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <arm_group_label>Ibuprofen 1800 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for Etoricoxib 90 mg</intervention_name>
    <description>One tablet once daily</description>
    <arm_group_label>Etoricoxib 120 mg</arm_group_label>
    <arm_group_label>Ibuprofen 1800 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for Ibuprofen</intervention_name>
    <description>One tablet three times daily</description>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <arm_group_label>Etoricoxib 120 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is in generally good health and is scheduled to have a total knee replacement

        Exclusion Criteria:

        - Is allergic, intolerant to, or has a history of a significant clinical or laboratory
        adverse experience associated with etoricoxib or other

        cyclooxygenase-2 (COX-2) inhibitors/non-steroidal anti-inflammatory drugs (NSAIDs),
        ibuprofen, morphine, or oxycodone, or has hypersensitivity to aspirin, or other NSAIDs

          -  Has uncontrolled hypertension

          -  Is currently a user of any illicit drugs, or has a history of drug or alcohol abuse
             within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

